Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable/Metastatic Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT05907304
What this trial is testing

Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Who this might be right for
Advanced or Metastatic Solid Tumors
Erasca, Inc. 86
Testing effectiveness (Phase 2)Ended earlyNCT01754376
What this trial is testing

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07576725
What this trial is testing

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+40 more
Fred Hutchinson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT00602576
What this trial is testing

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Who this might be right for
Melanoma (Skin)
Abramson Cancer Center at Penn Medicine 169
Early research (Phase 1)Ended earlyNCT04967196
What this trial is testing

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+1 more
Mayo Clinic 6
Very early researchNot Yet RecruitingNCT07700121
What this trial is testing

PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma

Who this might be right for
Unresectable or Metastatic Melanoma
Abramson Cancer Center at Penn Medicine 10
Testing effectiveness (Phase 2)Ended earlyNCT00082875
What this trial is testing

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

Who this might be right for
Stage III MelanomaStage IV Melanoma
National Cancer Institute (NCI) 56
Testing effectiveness (Phase 2)Study completedNCT01927419
What this trial is testing

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

Who this might be right for
Unresectable MelanomaMetastatic Melanoma
Bristol-Myers Squibb 142
Early research (Phase 1)Study completedNCT05303493
What this trial is testing

Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma

Who this might be right for
NSCLC Stage IVMelanoma Stage IVUnresectable Melanoma+1 more
Centre hospitalier de l'Université de Montréal (CHUM) 45
Testing effectiveness (Phase 2)Ended earlyNCT01551693
What this trial is testing

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
Dana-Farber Cancer Institute 3
Testing effectiveness (Phase 2)Study completedNCT01990859
What this trial is testing

Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients

Who this might be right for
Melanoma
Bristol-Myers Squibb 20
Early research (Phase 1)WithdrawnNCT04759846
What this trial is testing

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Who this might be right for
BRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more
Pierre Fabre Medicament
Large-scale testing (Phase 3)Study completedNCT00324727
What this trial is testing

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Who this might be right for
Intraocular MelanomaMelanoma (Skin)Metastatic Cancer
Delcath Systems Inc. 93
Large-scale testing (Phase 3)Active Not RecruitingNCT06054555
What this trial is testing

Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma
Amgen 633
Early research (Phase 1)Study completedNCT02032810
What this trial is testing

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Who this might be right for
MelanomaSkin Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Early research (Phase 1)Study completedNCT00112476
What this trial is testing

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Who this might be right for
Recurrent MelanomaRecurrent Renal Cell CancerStage IV Melanoma+2 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122522
What this trial is testing

Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Who this might be right for
Metastatic Melanoma
Memorial Sloan Kettering Cancer Center 70
Early research (Phase 1)Study completedNCT01638533
What this trial is testing

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Who this might be right for
GliomaHematopoietic and Lymphoid Cell NeoplasmLymphoma+47 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT03999749
What this trial is testing

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
NYU Langone Health 71
Next Page